As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
ORGANIZATION
Prioritize Cardiovascular Disease on Health Policy Agenda: CfHH to G7
Ahead of a meeting of G7 health ministers in Japan, a non-profit group combating cardiovascular disease renewed its call for concerted efforts to raise the priority of this “silent pandemic” towards the top of the global health policy agenda. Kosh…
To read the full story
ORGANIZATION
- Protect Info for Off-Patent Brands Even after Market Exit: JEMA
May 29, 2023
- Eisai’s Yasushi Okada Becomes FPMAJ Chairman
May 26, 2023
- New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
- 12 Medical and Nursing Care Groups Demand Responses to Inflation, Wage Hikes
May 26, 2023
- Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…